South San Francisco (April 18, 2005) – Hana Biosciences, Inc. today announced preclinical data of its oral radiation sensitizer IPdR. The data on IPdR will be presented as a poster presentation at the 2005 American Association of Cancer Research Annual Meeting in Anaheim, California, on April 19, 2005. Using a human U87 glioblast...

Hana Biosciences, Inc. (OTCBB:HNAB) announced positive results of a pilot pharmacokinetic clinical trial that was conducted using its proprietary lingual spray version of ondansetron hydrochloride (the active ingredient marketed under the brand name Zofran® by GlaxoSmithKline) for the treatment of chemotherapy-induced nausea and vomiting....

South San Francisco, CA. (February 24, 2005) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company headquartered in South San Francisco, will present at the Wells Fargo Securities 2005 HealthCare Conference on Tuesday, March 1, at The St. Regis Hotel in New York City. Mark Ahn, Ph.D., President and CEO will provide a compan...

South San Francisco, CA. (February 9, 2005) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company headquartered in South San Francisco, announced today an initial clinical study that will compare the pharmacokinetic profile of the lingual spray formulation of ondansetron to the approved oral dosage of Zofran ®, the world's b...

South San Francisco (January 18, 2005) – Hana Biosciences, Inc. announced today that the Securities and Exchange Commission has declared effective the Form SB-2 resale registration statement that the company filed with the Securities and Exchange Commission. Hana filed and requested the SB-2 resale registration statement to satisfy certai...

Pre-Clinical Study Shows IPdR Effective in Inducing Human Colon Cancer Xenograft Radiosensitization in Drug Resistant DNA Mismatch Repair- Proficient and – Deficient tumor models. Pre-clinical Toxicology Being Extended to Match Standards o...

South San Francisco (November 9, 2004) – Hana Biosciences, Inc. (OTCBB: HNAB) a biopharmaceutical company headquartered in South San Francisco, California, announced today that Russell L. Skibsted has been named Vice President and Chief Financial Officer, effective November 15, 2004. Mr. Skibsted most recently served as chief financial...

South San Francisco (October 27, 2004) – Hana Biosciences, Inc. (OTCBB: HNAB), a biopharmaceutical company headquartered in South San Francisco, California announced today that it has licensed exclusive U.S. and Canadian rights to a proprietary lingual spray formulation of the anti-emetic compound ondansetron hydrochloride, the active ...

South San Francisco (October 20, 2004) – Hana Biosciences, Inc. a biopharmaceutical company headquartered in South San Francisco, California, announced today that Robert A. Figlin, M.D., F.A.C.P., has joined the company's scientific advisory board. Dr. Figlin is Professor of Medicine and Urology, and holds the Henry Alvin and C...

South San Francisco (October 12, 2004) – Hana Biosciences, Inc. a biopharmaceutical company headquartered in South San Francisco, California, announced today Mark Ahn, Ph.D. President and Chief Executive Officer will be presenting at the Bio Emerging Investor Forum on October 13, 2004, at 10:50AM PT. The presentation will be held at th...